European experience on the practical use of levosimendan in patients with acute heart failure syndromes

• Type: Article in International Scientific Journal
• Date: 2005

Authors

Follath, F (Author) Other; Franco, F (Author) Other; Silva Cardoso, J (Author) FMUP

Journal

Title: American Journal of Cardiology

Vol. 96

Pages: 80G-85G

ISSN: 0002-9149

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 26 Citations

Scopus - 36 Citations

Other information

Authenticus ID: P-000-1B4

DOI: 10.1016/j.amjcard.2005.07.025

Abstract (EN): The novel calcium sensitizer and ATP-dependent potassium channel opener levosimendan has been introduced for routine use in several European countries. Recent reports on clinical experience confirm the positive hemodynamic results and beneficial clinical effects described in the initial dose-finding and randomized comparative therapeutic trials in patients with severe low-output heart failure. In addition, studies in small series-of patients with cardiogenic shock after myocardial infarction and/or surgical interventions and postinterventional myocardial dysfunction (stunning) indicate that the inotropic and vasodilating actions of,levosimendan may be of value in a wider range of indications. Dose recommendations, combination with other drugs, and potential side effects are discussed in this overview. (c) 2005 Elsevier Inc.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6